This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (53)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Cerebrovascular Disease  • Stroke  • Cardiovascular System  • Alert me on articles by topic

Irene L. Katzan, MD, MS; Maxim D. Hammer, MD; Eric D. Hixson, MBA; Anthony J. Furlan, MD; Alex Abou-Chebl, MD; Deborah M. Nadzam, PhD, RN; for the Cleveland Clinic Health System Stroke Quality Improvement Team

Arch Neurol. 2004;61:346-350.

Background  Intravenous tissue plasminogen activator (tPA) is the only approved therapy for acute ischemic stroke, although only 2% of patients with stroke receive intravenous tPA nationally.

Objective  To determine the rate of tPA use for stroke in the Cleveland, Ohio, community and the reasons why patients were excluded from thrombolysis treatment.

Design  Retrospective cohort study.

Setting  Community.

Subjects  Patients admitted because of stroke to the 9 Cleveland Clinic Health System hospitals from June 15, 1999, to June 15, 2000.

Main Outcome Measures  Utilization of intravenous tPA and reasons for ineligibility.

Results  There were 1923 admissions for ischemic stroke in the 1-year period. Of these, 288 (15.0%) arrived within the 3-hour time window, and approximately 6.9% were considered eligible for tPA. The most common reasons for exclusion among patients arriving within 3 hours were mild neurologic impairment and rapidly improving symptoms. The overall rate of tPA use among patients presenting within 3 hours was 19.4%, and the rate of use among eligible patients was 43.4% (n = 56). The use of tPA did not differ significantly according to race or sex.

Conclusions  Only 15% of patients arrived within the 3-hour time window for intravenous tPA, making delay in presentation the most common reason patients were ineligible for IV thrombolysis. Neurologic criteria were the second most common group of exclusions. Overall tPA use was low, but it was used in nearly half of all patients with no documented contraindications. Intravenous tPA use in a community setting can compare favorably with the rate of use seen in academic medical settings.

From the Department of Neurology, Cleveland Clinic Foundation, Cleveland, Ohio (Drs Katzan, Hammer, Furlan, and Abou-Chebl); Quality Institute, Cleveland Clinic Health System (Mr Hixson and Dr Nadzam); and Center for Health Care Research and Policy, MetroHealth Medical Center, Cleveland (Dr Katzan).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Strengthening the Link: The Critical Role of Children in the Stroke Chain of Recovery
Davis
Stroke 2008;39:2695-2696.
FULL TEXT  

Rural-Urban Differences in Acute Stroke Management Practices: A Modifiable Disparity
Leira et al.
Arch Neurol 2008;65:887-891.
ABSTRACT | FULL TEXT  

Potential for quality improvement of acute stroke management in a district general hospital
McCarron et al.
Emerg. Med. J. 2008;25:270-273.
ABSTRACT | FULL TEXT  

Influence of the stroke code activation source on the outcome of acute ischemic stroke patients
de la Ossa et al.
Neurology 2008;70:1238-1243.
ABSTRACT | FULL TEXT  

National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate
Kleindorfer et al.
Stroke 2008;39:924-928.
ABSTRACT | FULL TEXT  

Sex Differences in Acute Stroke Care in a Statewide Stroke Registry
Gargano et al.
Stroke 2008;39:24-29.
ABSTRACT | FULL TEXT  

Acute Ischemic Stroke Treatment in 2007
Goldstein
Circulation 2007;116:1504-1514.
FULL TEXT  

Performance Measures in Neuroradiology
Seidenwurm et al.
Am. J. Neuroradiol. 2007;28:1435-1438.
ABSTRACT | FULL TEXT  

Outcome of Stroke With Mild or Rapidly Improving Symptoms
Nedeltchev et al.
Stroke 2007;38:2531-2535.
ABSTRACT | FULL TEXT  

National Healthline Responses to a Stroke Scenario: Implications for Early Intervention
Jarrell et al.
Stroke 2007;38:2376-2378.
ABSTRACT | FULL TEXT  

Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study
Dirks et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:685-689.
ABSTRACT | FULL TEXT  

CT-NIHSS Mismatch Does Not Correlate With MRI Diffusion-Perfusion Mismatch
Messe et al.
Stroke 2007;38:2079-2084.
ABSTRACT | FULL TEXT  

Community Stroke Education Using Mass Media: Past Results and Future Implications
Davis
Stroke 2007;38:2034-2035.
FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Adams et al.
Circulation 2007;115:e478-e534.
ABSTRACT | FULL TEXT  

Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Adams et al.
Stroke 2007;38:1655-1711.
ABSTRACT | FULL TEXT  

Leading the Elephant Out of the Corner: The Future of Health Care: Presidential Address at the American Heart Association 2006 Scientific Sessions
Gibbons
Circulation 2007;115:2221-2230.
FULL TEXT  

Slow Progressive Acceptance of Intravenous Thrombolysis for Patients With Stroke by Rural Primary Care Physicians
Leira et al.
Arch Neurol 2007;64:518-521.
ABSTRACT | FULL TEXT  

Early MRI and outcomes of untreated patients with mild or improving ischemic stroke.
Rajajee et al.
Neurology 2006;67:980-984.
ABSTRACT | FULL TEXT  

Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion
Mahmoud et al.
Br. J. Ophthalmol. 2006;90:911-915.
ABSTRACT | FULL TEXT  

Rapid stent-supported revascularization in acute ischemic stroke.
Fitzsimmons et al.
Am. J. Neuroradiol. 2006;27:1132-1134.
ABSTRACT | FULL TEXT  

Reasons for exclusion from thrombolytic therapy following acute ischemic stroke
Schestatsky et al.
Neurology 2005;65:1844-1844.
FULL TEXT  

Part 9: Adult Stroke
Circulation 2005;112:IV-111-IV-120.
FULL TEXT  

Potential Applicability of Recombinant Factor VIIa for Intracerebral Hemorrhage
Flaherty et al.
Stroke 2005;36:2660-2664.
ABSTRACT | FULL TEXT  

Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke
Smith et al.
Stroke 2005;36:2497-2499.
ABSTRACT | FULL TEXT  

The impact of standardized stroke orders on adherence to best practices
California Acute Stroke Pilot Registry (CASPR) Inv
Neurology 2005;65:360-365.
ABSTRACT | FULL TEXT  

Prioritizing interventions to improve rates of thrombolysis for ischemic stroke
California Acute Stroke Pilot Registry (CASPR) Inv
Neurology 2005;64:654-659.
ABSTRACT | FULL TEXT  

Telemedicine for Safe and Extended Use of Thrombolysis in Stroke: The Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria
Audebert et al.
Stroke 2005;36:287-291.
ABSTRACT | FULL TEXT